Activities of nine antifungal agents against Candida auris biofilms.

Mycoses

Laboratory of Infectious Diseases, 3rd Department of Pediatrics, Medical Faculty, Aristotle University School of Health Sciences, Hippokration General Hospital, Thessaloniki, Greece.

Published: April 2021

Background: Candida auris is a newly described multidrug-resistant fungal pathogen associated with biofilm formation and severe infections with high mortality.

Objectives: To study the activities of fluconazole, itraconazole, posaconazole, voriconazole, deoxycholate and liposomal amphotericin B, anidulafungin, caspofungin and micafungin against C auris biofilms and planktonic cells.

Materials/methods: C auris strains originating from 5 clades (South Asian, East Asian, African, South American and Iranian) were tested for biofilm production by safranin staining of the extracellular matrix polysaccharide structure as well as biofilm (BF) and planktonic (PLK) antifungal susceptibility to nine antifungal agents using the XTT reduction assay.

Results: Candida auris isolates produced mature BF as compared to non-C auris control (Candida albicans and Candida parapsilosis) strains. Four C auris isolates exhibited relatively high MIC's for fluconazole (32-128 mg/L for PLK MIC and 128-1024 mg/L for BF MIC) as compared to the Iranian strain that had PLK and BF MIC's 0.5 and 16, respectively. Itraconazole, posaconazole and voriconazole had relatively low PLK MICs but high BF MICs. A similar pattern was observed with echinocandins; relatively low PLK MIC (0.06-4 mg/L) but quite high BF MICs (4-2048 mg/L). While all isolates exhibited relatively low PLK MICs (0.06-4 mg/L) for both amphotericin B formulations, liposomal amphotericin B showed higher MICs compared to deoxycholate amphotericin B against C auris BF.

Conclusion: Triazoles, echinocandins and liposomal amphotericin B appear to have less activity against C auris biofilms than deoxycholate amphotericin B. Our in vitro model provides evidence for intrinsic C auris biofilm resistance to antifungal agents.

Download full-text PDF

Source
http://dx.doi.org/10.1111/myc.13223DOI Listing

Publication Analysis

Top Keywords

antifungal agents
12
candida auris
12
liposomal amphotericin
12
low plk
12
itraconazole posaconazole
8
posaconazole voriconazole
8
c auris biofilms
8
auris isolates
8
isolates exhibited
8
plk mic
8

Similar Publications

Background: Superficial fungal infections are among the most common infections in world, they mainly affect skin, nails and scalp without further invasion. Superficial fungal diseases are conventionally diagnosed with direct microscopy, fungal culture or histopathology, treated with topical or systemic antifungal agents and prevented in immunocompetent patients by improving personal hygiene. However, conventional diagnostic tests can be time-consuming, also treatment can be insufficient or ineffective and prevention can prove to be demanding.

View Article and Find Full Text PDF

Pharmacokinetic Boosting of Calcineurin Inhibitors in Transplantation: Pros, Cons, and Perspectives.

Ther Drug Monit

February 2025

Service de Pharmacologie, Toxicologie et Pharmacovigilance, CHU Limoges, Limoges, France.

The concept of pharmacokinetic (PK) boosting of calcineurin inhibitors (CNI) emerged after the FDA approval of cyclosporine-A. Several studies followed, and the proof of concept was well established by the late 1990s. This also continued for the next blockbuster immunosuppressant, tacrolimus.

View Article and Find Full Text PDF

Pulmonary overlap syndrome in a patient with bronchial asthma.

BMJ Case Rep

January 2025

Pulmonary, Critical Care and Sleep Medicine, ESICPGIMSR, New Delhi, Delhi, India.

Allergic bronchopulmonary aspergillosis (ABPA) is a disease of immunocompetent patients, and invasive pulmonary aspergillosis is seen in immunocompromised patients. Hence, pulmonary overlap syndrome presenting with ABPA and invasive aspergillosis is extremely rare. We report a case of well-controlled bronchial asthma who presented with acute exacerbation and hypoxaemic respiratory failure.

View Article and Find Full Text PDF

sp. nov., a potently antifungal bacterium isolated from moss.

Int J Syst Evol Microbiol

January 2025

Department of Microbiology, Institute of Plant and Microbial Biology, University of Zrich, Zurich, Switzerland.

A novel strain, 681, was isolated from a moss sample taken from the Chrutzelried woods in Canton Zürich, Switzerland. The strain showed potent activity against several fungi and oomycetes. It was affiliated to the genus by 16S rRNA gene sequence phylogeny.

View Article and Find Full Text PDF

Natural products in the treatment of diabetic foot infection.

Eur J Med Res

January 2025

Research Center for Molecular Medicine, Institute of Cancer, Avicenna Health Research Institute, Hamadan University of Medical Sciences, Hamadan, Iran.

Diabetic foot infections (DFIs) are a significant complication in diabetes mellitus, leading to increased morbidity, hospitalizations, and healthcare burdens. The growing prevalence of antibiotic-resistant pathogens has reduced the efficacy of conventional treatments, highlighting the need for alternative therapeutic strategies. Natural products, known for their antimicrobial, anti-inflammatory, and wound-healing properties, have garnered attention as potential treatments for DFIs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!